Replacing a systematic PB with mpMRI ±TB as part of an AS protocol increased the likelihood of re-classifying patients on AS and identifying men with clinically significant disease requiring treatment. mpMRI ±TB as part of AS thereby represents a significant advance in the oncological safety of the AS protocol.
The human immunodeficiency virus (HIV) can cause diverse cardiovascular complications. In HIV patients on antiretroviral therapy, the prevalence of myocardial infarction has steadily increased over the years. Young patients who are naïve to antiretroviral therapy and who experience coronary events are not well represented in the medical literature. We describe the case of a 22-year-old man, infected with HIV for 4 years and never treated with antiretroviral therapy, who emergently presented with a non-ST-segment-elevation myocardial infarction. Coronary angiograms revealed thrombosis and multiple coronary artery aneurysms; however, no areas of atherosclerotic stenosis were apparent. He was successfully treated with coronary stenting, antiplatelet therapy, and anticoagulation. Nine months after the initial presentation, he exhibited excellent exercise capacity, and no ischemia was evident. We discuss the various therapeutic approaches in this case.
PurposePermacol has been gaining popularity in recent times for the treatment of fecal incontinence (FI). This study aims to evaluate the safety and efficacy of anal submucosal Permacol injection in the treatment of FI.MethodsAll consecutive patients who underwent Permacol injection for FI over a 3-year period were included. Patients' data relating to obstetric history, anorectal/pelvic operations, type of FI, preoperative anorectal physiology results and follow-up details for outcome measures were collected. Preoperative and postoperative Cleveland Clinic Florida Incontinence Scores (CCFISs) were noted. Patients were surveyed by using a telephone questionnaire to assess the quality of life and other outcome measures. Data were analysed using SPSS ver.19.0.ResultsThirty patients (28 females and 2 males) with a median age of 67 years were included in the study. Of those patients, 37%, 50%, and 13% were noted to have passive, mixed and urge FI, respectively. Six of the patients (20%) had repeat Permacol injections, 5 of whom had sustained responses to the first Permacol injection for a mean of 11 months. There was a significant improvement in the CCFIS from a baseline median of 12.5, mean 12.8 interquartile range [IQR], 6–20), to a median of 3.5, mean 4.8 (IQR, 0–20), P < 0.001. Of the patients surveyed by telephone 89% were satisfied with their overall experience and the improvement in their symptoms following Permacol injections.ConclusionThis study has demonstrated that Permacol injection for the treatment of FI is safe and effective and has no associated major complications. However, the results are not permanent; consequently, a significant proportion of the patients with an initial response may require repeat injections.
Background Active surveillance (AS) is a strategy employed as an alternative to immediate standard active treatments for patients with low or intermediate-risk localised prostate cancer (PCa). Active treatments such as radical prostatectomy and radiotherapy are associated with significant adverse effects which impair quality of life. There is robust data indicating that the majority of patients with lowrisk PCa undergo a slow and predictable course of cancer growth, and hence do not require immediate active curative treatment. AS provides a means to identify patients with low-risk PCa to be monitored closely through regular clinical assessments, PSA testing, imaging using MRI scans and regular repeat prostate biopsies. These measures enable the identification of any change in disease characteristics which indicate progression or increase in cancer extent or aggressiveness, which necessitates active curative treatment. Alternatively, some patients may choose to leave AS to pursue curative interventions due to anxiety or development of adverse effects such as infections from regular repeat biopsies. The main benefit of AS is the avoidance of unnecessary radical treatments for patients at the early stages of the disease, hence avoiding over-treatment, whilst identifying those at risk of progression to be treated actively. The objective of this article is to provide a narrative summary of contemporary practice regarding AS based on a review of the available evidence base and clinical practice guidelines.Elements of discussion include the potential clinical effectiveness and harms of AS, what AS involves from a practical perspective for healthcare professionals, and patient perspectives. The pitfalls and challenges for healthcare professionals undertaking AS due to variable definitions and thresholds are also considered. Data sources We consulted international guidelines, national and international collaborative studies and seminal prospective studies on AS in the management of clinically localised PCa. Therefore this article constitutes a narrative review and critique of the current evidence base regarding AS. Conclusions AS is a feasible alternative to radical treatment options, especially for lowrisk PCa, primarily as a means of avoiding over-treatment for patients with early disease, whilst identifying those who are at risk of disease progression for active treatment. There is emerging data demonstrating the long-term safety of AS as an oncological management strategy. Uncertainties remain regarding variation in definitions, criteria, thresholds and the most effective types of diagnostic interventions pertaining to patient selection, monitoring and reclassification. Efforts have been made to standardise the practice and conduct of AS, and these are continuing. As data from high-quality prospective comparative studies mature, the practice of AS will continue to evolve and outcomes are expected to continue to improve. Implications for nursing practice The practice of AS involves a multi-disciplinary team of healthca...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.